-
CRISPR Therapeutics' (CRSP) "Buy" Rating Reiterated at Needham & Company LLC
Source: Buzz FX / 14 Jan 2025 07:36:16 America/Chicago
CRISPR Therapeutics' (CRSP) "Buy" Rating Reiterated at Needham & Company LLC Written by MarketBeat January 14, 2025 Share Link copied to clipboard. CRISPR Therapeutics ( NASDAQ:CRSP - Get Free Report ) 's stock had its "buy" rating reaffirm
Read more...